Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at the Trunk

NCT01102387 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT01102387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01102387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at the Trunk
Lead sponsor
Almirall, S.A.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
July 31, 2011
Enrollment
137 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

candidiasis